This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is providing $238,500.00 to the University of California, San Diego (UCSD) to develop new RNA therapeutic technology to target Alzheimer's disease (AD). The project aims to generate a highly effective phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic that can efficiently escape endosomes to selectively target the amyloid precursor protein (APP) and prevent the pathogenesis of AD. The research will be tested and optimized in a humanized APP mouse model of Alzheimer's disease. The project period is from December 1, 2024 to November 30, 2026.
Generated 3/25/25, 3:35 AM